Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PLIANT THERAPEUTICS, INC.

(PLRX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Pliant Therapeutics : Posts Positive Preliminary Results From Clinical Trial For Idiopathic Pulmonary Fibrosis Treatment

09/07/2021 | 10:24am EST


© MT Newswires 2021
All news about PLIANT THERAPEUTICS, INC.
11/24Pliant Therapeutics Initiated at Outperform, Speculative Risk by RBC, Price Target Star..
MT
11/18Pliant Therapeutics to Participate in Upcoming Investor Conferences
GL
11/09Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2021 Financial ..
PU
11/09PLIANT THERAPEUTICS, INC. : Results of Operations and Financial Condition (form 8-K)
AQ
11/09PLIANT THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition ..
AQ
11/09Pliant Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Month..
CI
11/09Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2021 Financial ..
AQ
11/03HC Wainwright Starts Pliant Therapeutics at Buy With $45 Price Target
MT
10/07PLIANT THERAPEUTICS : to Participate in Piper Sandler Lung Day
AQ
09/07PLIANT THERAPEUTICS : Posts Positive Preliminary Results From Clinical Trial For Idiopathi..
MT
More news
Analyst Recommendations on PLIANT THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2021 7,82 M - -
Net income 2021 -101 M - -
Net cash 2021 186 M - -
P/E ratio 2021 -4,38x
Yield 2021 -
Capitalization 442 M 442 M -
EV / Sales 2021 32,8x
EV / Sales 2022 51,6x
Nbr of Employees 90
Free-Float 90,5%
Chart PLIANT THERAPEUTICS, INC.
Duration : Period :
Pliant Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PLIANT THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 12,27 $
Average target price 47,40 $
Spread / Average Target 286%
EPS Revisions
Managers and Directors
Bernard Coulie President, Chief Executive Officer & Director
Keith Lamont Cummings Chief Financial Officer
Ho Young Huh Chairman
Eric Lefebvre Chief Medical Officer
Gregory P. Cosgrove Vice President-Clinical Development
Sector and Competitors
1st jan.Capi. (M$)
PLIANT THERAPEUTICS, INC.-41.46%442
JOHNSON & JOHNSON1.27%419 583
ROCHE HOLDING AG17.62%341 364
PFIZER, INC.44.09%304 610
NOVO NORDISK A/S64.51%244 010
ELI LILLY AND COMPANY47.55%222 641